PeerView Gastroenterology CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

All episodes

Best episodes

Top 10 PeerView Gastroenterology CME/CNE/CPE Audio Podcast Episodes

Goodpods has curated a list of the 10 best PeerView Gastroenterology CME/CNE/CPE Audio Podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to PeerView Gastroenterology CME/CNE/CPE Audio Podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite PeerView Gastroenterology CME/CNE/CPE Audio Podcast episode by adding your comments to the episode page.

Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

04/29/22 • 31 min

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Andrea Cercek, MD - Accelerating Personalized Care in CRC: The Prominent Role of Predictive Biomarkers and Immunotherapy Platforms in Early and Advanced Disease

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

11/12/24 • 39 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JXZ865. CME/MOC/AAPA/IPCE credit will be available until November 7, 2025.

Accelerating Personalized Care in CRC: The Prominent Role of Predictive Biomarkers and Immunotherapy Platforms in Early and Advanced Disease

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported by an independent medical education grant from GSK.

Disclosure information is available at the beginning of the video presentation.

Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

04/01/20 • 82 min

Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice

Gayle Jameson, MSN, ACNP-BC, AOCN - Clinical Advances in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in a Changing Therapeutic Landscape

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

06/10/19 • 70 min

Oncology nurses are at the forefront of care for patients with pancreatic cancer, a much-feared disease whose management was for years characterized by modestly effective treatment options. The recent emergence of new cytotoxic platforms combined with rapid research on potent targeted therapies has made the role of the nurse as a caregiver and educator more important than ever, particularly because these new options differ greatly from conventional chemotherapy strategies. In this activity based on a recent live symposium held in Anaheim during the Oncology Nursing Society’s (ONS) 44th Annual Congress, expert nurse faculty use a patient-voice inclusive MasterClass designed to provide real-world guidance for effective translation of the latest evidence into clinical practice. In addition, the experts offer their perspectives on the unique needs and concerns of patients, and how engagement strategies can shape individualized, patient-centric management plans throughout the continuum of pancreatic cancer care. This activity also features perspectives from pancreatic cancer patients developed in collaboration with Let’s Win, an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on therapeutic strategies in pancreatic cancer, including cytotoxic platforms and chemotherapy sequencing approaches, targeted agents directed against molecular features/mutations, or tumor treating field therapy, among others, Educate patients on the clinical uses and potential of clinical trials investigating novel therapeutics alone and in combination with cytotoxic regimens in the pancreatic cancer setting, Provide guidance to patients on therapeutic sequencing with cytotoxic platforms in advanced pancreatic cancer based upon available evidence, guideline recommendations, and disease- and patient-specific characteristics, Manage adverse events associated with established and emerging therapies for pancreatic cancer.

Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

09/15/21 • 59 min

Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.

Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

08/25/22 • 64 min

Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Rohit Loomba, MD, MHSc - Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

06/11/24 • 57 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RNX865. CME credit will be available until June 19, 2025.

Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

Riad Salem, MD, MBA / Mark Yarchoan, MD - Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

06/11/24 • 57 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.

Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Milind Javle, MD - Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

02/20/24 • 90 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.

Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.

Faculty/Planner
Tanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.

Faculty/Planner
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE acti...

Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

12/21/23 • 23 min

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EGP865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.

Show more best episodes

FAQ

How many episodes does PeerView Gastroenterology CME/CNE/CPE Audio Podcast have?

PeerView Gastroenterology CME/CNE/CPE Audio Podcast currently has 113 episodes available.

What topics does PeerView Gastroenterology CME/CNE/CPE Audio Podcast cover?

The podcast is about Health & Fitness, Cme, Medicine, Podcasts, Science, Medical Education and Gastroenterology.

What is the most popular episode on PeerView Gastroenterology CME/CNE/CPE Audio Podcast?

The episode title 'Ikuo Hirano, MD - On the Cusp of a New Era in Treatment for Eosinophilic Esophagitis: Expert Insights on the Latest Advances in Targeted Therapy' is the most popular.

What is the average episode length on PeerView Gastroenterology CME/CNE/CPE Audio Podcast?

The average episode length on PeerView Gastroenterology CME/CNE/CPE Audio Podcast is 61 minutes.

How often are episodes of PeerView Gastroenterology CME/CNE/CPE Audio Podcast released?

Episodes of PeerView Gastroenterology CME/CNE/CPE Audio Podcast are typically released every 14 days.

When was the first episode of PeerView Gastroenterology CME/CNE/CPE Audio Podcast?

The first episode of PeerView Gastroenterology CME/CNE/CPE Audio Podcast was released on Jan 11, 2019.

Show more FAQ

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

Top 10 PeerView Gastroenterology CME/CNE/CPE Audio Podcast Episodes

FAQ

How many episodes does PeerView Gastroenterology CME/CNE/CPE Audio Podcast have?

What topics does PeerView Gastroenterology CME/CNE/CPE Audio Podcast cover?

What is the most popular episode on PeerView Gastroenterology CME/CNE/CPE Audio Podcast?

What is the average episode length on PeerView Gastroenterology CME/CNE/CPE Audio Podcast?

How often are episodes of PeerView Gastroenterology CME/CNE/CPE Audio Podcast released?

When was the first episode of PeerView Gastroenterology CME/CNE/CPE Audio Podcast?

Comments